Doray et al 2 correlated prenatal ultrasound US with postnatal diagnoses in 47 fetuses with skeletal dysplasia and found it difficult to accurately diagnose the specific skeletal dysplasia. Lethal skeletal dysplasias such as type II osteogenesis imperfecta and thanatophoric dysplasia present early with long bone measurements falling far below the fifth percentile for gestational age by the second trimester. With achondroplasia, limb measurements are typically normal in the first and early second trimester. Drop off of femoral and humeral measurements may be noted at 20 to 24 weeks with a more marked decrease in growth rate apparent in the third trimester 1. The key to distinguishing between homozygous and heterozygous achondroplasia is careful observation of growth in the second trimester it is this trimester that the fetus demonstrates much less interval growth of the femur than expected 3.
|Published (Last):||23 July 2014|
|PDF File Size:||3.2 Mb|
|ePub File Size:||7.53 Mb|
|Price:||Free* [*Free Regsitration Required]|
Received Aug 6; Accepted Sep Abstract To perform a reliable non-invasive detection of the fetal achondroplasia using maternal plasma. This method was applied in a non-invasive detection of the fetal achondroplasia using circulating fetal-DNA cf-DNA in maternal plasma.
In a woman carrying a normal fetus, analysis of cf-DNA showed only one peak of the wild-type G allele. In a woman expected an achondroplasia fetus, analysis of cf-DNA showed the two peaks of wild-type G allele and mutant-type A allele and accurately detected the fetal achondroplasia. Conclusions The non-invasive method using maternal plasma and QF-PCR may be useful for diagnosis of the fetal achondroplasia.
It results from an autosomal dominant mutation in the fibroblast growth factor receptor 3 gene FGFR3. The majority of cases appear to be de novo mutations. Achondroplasia is generally detected by abnormal prenatal ultrasound findings in the third trimester of pregnancy. These invasive procedures present a small but significant risk for both the fetus and mother.
Therefore, non-invasive procedures using circulating fetal DNA cf-DNA in maternal plasma have been studied for the detection of the fetal achondroplasia mutation and improved via applications of various molecular methods. However, these methods required a large volume of maternal blood and additional size fractionation process. Therefore, we considered a method to detect the fetal achondroplasia with a small volume of maternal blood without size fractionation process and developed a modified method that combined RFLP with a quantitative fluorescence-PCR QF-PCR.
Here we present data showing that a modified QF-PCR can be performed on a small quantity of achondroplasia DNA and this method can be used to confidently detect the fetal achondroplasia in maternal plasma.
The lower limit of detection as well the inter-assay precision was determined using 1-in-2 dilution steps and five replicates. The cf-DNA was extracted from 0. The reverse primer was labeled with 6-carboxyfluorescein. The PCR reaction solution contained 10 pM primers, 0. Restriction digestion was used to distinguish the alleles in the FGFR3 polymorphic region.
QF-PCR results were confirmed by direct sequencing. Corresponding genotypes were assigned using Genotyper software version 3. The inter-assay precision was presented as coefficient of variation CV. Statistical analysis was performed using Microsoft Excel. Peak height of wild-type G allele was not different among the dilution factors. However, peak height of mutant-type A allele and allelic ratio were reduced in a dilution factor-dependent manner.
However, direct sequencing could not detect the fetal achondroplasia mutation in these dilution factors data not shown.
MR imaging of the craniovertebral junction, cranium, and brain in children with achondroplasia. Pediatric patients with achondroplasia: CT evaluation of the craniocervical junction. Radiology abstract - Pubmed citation 3. Mortality in achondroplasia study: a year follow-up. Posterior fossa arachnoid cysts and cerebellar tonsillar descent: short review.
Esto significa que los padres son de altura promedio y no tienen el gen anormal. Tener un padre con acondroplasia aumenta el riesgo de nacer con la enfermedad. Sin embargo, diferentes tipos de tratamiento se puede llevar a cabo para ayudar a aliviar los problemas causados por la enfermedad. Es necesario revisar el estado de la columna vertebral para prevenir problemas respiratorios. El tratamiento con hormona del crecimiento no afecta en gran medida la altura de una persona con acondroplasia.
Achondroplasia in Children
Received Aug 6; Accepted Sep Abstract To perform a reliable non-invasive detection of the fetal achondroplasia using maternal plasma. This method was applied in a non-invasive detection of the fetal achondroplasia using circulating fetal-DNA cf-DNA in maternal plasma. In a woman carrying a normal fetus, analysis of cf-DNA showed only one peak of the wild-type G allele.
Non-invasive prenatal detection of achondroplasia using circulating fetal DNA in maternal plasma
Shortening of the proximal limbs called rhizomelic shortening Short fingers and toes with trident hands Large head with prominent forehead frontal bossing Small midface with a flattened nasal bridge Spinal kyphosis convex curvature or lordosis concave curvature Varus bowleg or valgus knock knee deformities Causes[ edit ] Achondroplasia is caused by a mutation in fibroblast growth factor receptor 3 FGFR3 gene. This protein contributes to the production of collagen and other structural components in tissues and bones. Cartilage is not able to fully develop into bone, causing the individual to be disproportionately shorter in height. In normal development FGFR3 has a negative regulatory effect on bone growth. In achondroplasia, the mutated form of the receptor is constitutively active and this leads to severely shortened bones. The effect is genetically dominant , with one mutant copy of the FGFR3 gene being sufficient to cause achondroplasia, while two copies of the mutant gene are invariably fatal recessive lethal before or shortly after birth known as a lethal allele.